Gadobutrol
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ .
Adverse events should also be reported to GE HealthCare at
gpv.drugsafety@gehealthcare.com
About Gadobutrol
Gadobutrol is a high relaxivity macrocyclic GBCA expanding your choice of agents from GE HealthCare.1,2
Over 80% of GBCA use in Europe is accounted for by gadobutrol and gadoteric acid – we now manufacture and supply both.7
Image quality
Highly effective in both steady state and dynamic imaging2-6,12
Usage
Potential to improve diagnostic confidence across a broad range of indications11,13,14
Packaging
Meeting procedural needs, with packaging that prioritises your workplace safety and efficiency
Commitment
Gadobutrol is produced in Norway to the same exacting standards as our other contrast agents
References
2. Scott LJ. Clin Drug Investig 2018; 38(8): 773-84.
3. Szomolanyi P et al. Invest Radiol 2019; 54(9): 559-64.
4. Rohrer M et al. Invest Radiol 2005; 40(11): 715-24.
5. Shen Y et al. Invest Radiol 2015; 50(5): 330-8.
6. Noebauer-Huhmann IM et al. Invest Radiol 2010; 45(9): 554-8.
7. GE HealthCare Data on File_GBCA_Use.
8. Kramer JH et al. Invest Radiol 2013; 48(3): 121-8.
9. Durmus T et al. Invest Radiol 2012; 47(3): 183-8.
10. Hoelter P et al. Neuroradiology 2017; 59(12): 1233-9.
11. Gutierrez JE et al. Magn Reson Insights 2015; 8: 1-10.
12. Miller K et al. Imaging Med 2011; 3(1): 93–105.
13. Katakami N et al. Invest Radiol 2011; 46(7): 411-8.
14. Gadobutrol Summary of Product Characteristics.
15. Glutig K et al. Pediatr Radiol 2016; 46: 1317-23.
16. Prince MR et al. Eur Radiol. 2017; 27(1): 286-95.
17. Marshall G. Radiography 2008; 14: 128-34.
18. Gricar J et al. Radiol Manage 2007; SEP/OCT: 34-42.
19. Dhaliwal H et al. Int J Life Cycle Assess 2014; 19: 1965-73.
20. GE HealthCare Data on File, Investment November 2023.
cGMP: current good manufacturing practice
CNS: central nervous system
GBCA: gadolinium-based contrast agent
ICH: International Council for Harmonisation
MR: magnetic resonance
MRI: MR imaging